{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:15:36Z","timestamp":1788272136775,"version":"build-2803163510"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-CD38 monoclonal antibodies have become a central immunotherapeutic platform in multiple myeloma, where they have reshaped treatment across relapsed or refractory disease, frontline therapy, maintenance intensification, and minimal residual disease-oriented management. Their success in multiple myeloma has also stimulated broader development in immunoglobulin light-chain amyloidosis, selected hematologic malignancies, and humoral immune-mediated disorders. CD38 functions both as a surface target and as an ectoenzyme involved in nicotinamide adenine dinucleotide metabolism, calcium signaling, immune-cell regulation, and microenvironmental remodeling, providing a mechanistic basis for antibody-mediated cytotoxicity, immune modulation, and broader humoral immune intervention. This Review critically evaluates CD38 biology, Fc-mediated immune-effector mechanisms, immune remodeling, clinical evidence, resistance, safety, laboratory interferences, biomarker evidence, and clinical positioning of anti-CD38 antibodies, with multiple myeloma as the central reference disease. In immunoglobulin light-chain amyloidosis, daratumumab-based therapy has moved beyond myeloma-derived extrapolation and established a disease-specific framework integrating hematologic response, organ response, and survival outcomes. Beyond multiple myeloma, anti-CD38-based strategies have been investigated in light-chain amyloidosis, selected hematologic malignancies, autoimmune cytopenias, transplant-related alloimmunity, and other antibody-driven diseases. However, the strength of evidence differs substantially across these settings, and CD38 expression alone does not establish clinical benefit. Outside established plasma cell disorders, further development should therefore rely on disease-specific prospective evidence and careful assessment of safety.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1932951","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:32:06Z","timestamp":1788269526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning"],"prefix":"10.3389","volume":"17","author":[{"given":"Liming","family":"Yu","sequence":"first","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, First Clinical Medical College","place":["Jinan, China"]},{"name":"Shandong First Medical University Third Affiliated Hospital","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changnian","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, First Clinical Medical College","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dadong","family":"Guo","sequence":"additional","affiliation":[{"name":"Shandong Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Therapy of Ocular Diseases; Medical College of Optometry and Ophthalmology, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]},{"name":"Shandong Academy of Eye Disease Prevention and Therapy","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Institute of Hematology, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000760","article-title":"Endless possibilities and how to exploit them? What is the optimal treatment sequence","volume":"2025","author":"Chakraborty","year":"2025","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as theranostic target in oncology","volume":"22","author":"Bocuzzi","year":"2024","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/nejmoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2024-205077","article-title":"Subcutaneous daratumumab (DARA) + Bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: overall survival and final major organ deterioration progression-free survival results from the phase 3 andromeda study","volume":"144","author":"Kastritis","year":"2024","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024493","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study","volume":"144","author":"Bhatla","year":"2024","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003604","article-title":"Daratumumab for autoimmune diseases: a systematic review","volume":"9","author":"Holzer","year":"2023","journal-title":"RMD Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2025.14343","article-title":"Targeting CD38 in antibody-mediated rejection","volume":"38","author":"Mayer","year":"2025","journal-title":"Transpl Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401279","article-title":"Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL","volume":"13","author":"L\u00facio","year":"1999","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.6.2154","article-title":"The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression","volume":"99","author":"Medina","year":"2002","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multi-faceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbrc.2020.12.048","article-title":"Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma","volume":"536","author":"Lee","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo4271","article-title":"CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy","volume":"8","author":"Chen","year":"2022","journal-title":"Sci Adv"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2532446","article-title":"Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions","volume":"34","author":"Richardson","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287904","article-title":"FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q","volume":"111","author":"Kikuchi","year":"2026","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0695","article-title":"SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic Malignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco-25-00744","article-title":"Isatuximab subcutaneous by on-body injector versus isatuximab intravenous plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: phase III IRAKLIA study","volume":"43","author":"Ailawadhi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2025-3049","article-title":"Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia","volume":"146","author":"Kuter","year":"2025","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100043","article-title":"Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed\/refractory multiple myeloma","volume":"1","author":"Krishnan","year":"2024","journal-title":"Blood Neoplasia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2513120","article-title":"A phase 2 randomized trial of mezagitamab in primary immune thrombocytopenia","volume":"394","author":"Kuter","year":"2026","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084314","article-title":"Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial","volume":"391","author":"Chen","year":"2025","journal-title":"Bmj"},{"key":"B36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41392-025-02487-2","article-title":"Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib\/IIa trial","volume":"10","author":"Zhao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): A randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501351","article-title":"The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fc\u03b3 Receptor-mediated cross-linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/cancers13010076","article-title":"Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells","volume":"13","author":"Baum","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284325","article-title":"Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis","volume":"109","author":"Richardson","year":"2024","journal-title":"Haematologica"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-02266","article-title":"Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2025","journal-title":"J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(19)30249-2","article-title":"MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial","volume":"7","author":"Raab","year":"2020","journal-title":"Lancet Haematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14241","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects","volume":"86","author":"Fedyk","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma","volume":"106","author":"Kinder","year":"2021","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1410457","article-title":"Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): A randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial","volume":"11","author":"Yong","year":"2024","journal-title":"Lancet Haematol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/s1470-2045(25)00018-x","article-title":"Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"26","author":"Mateos","year":"2025","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287200","article-title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial","volume":"110","author":"Manier","year":"2025","journal-title":"Haematologica"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00280-3","article-title":"Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial","volume":"26","author":"Manier","year":"2025","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70448","article-title":"MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in \u2265VGPR\/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM","volume":"208","author":"Gozzetti","year":"2026","journal-title":"Br J Haematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.08.011","article-title":"Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial","volume":"4","author":"Minnema","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032099","article-title":"Daratumumab-bortezomib-cyclophosphamide-dexamethasone in newly diagnosed amyloidosis: ANDROMEDA final survival analysis","volume":"148","author":"Kastritis","year":"2026","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283325","article-title":"Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival","volume":"109","author":"Oubari","year":"2024","journal-title":"Haematologica"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032897","article-title":"A Phase 2 trial of daratumumab monotherapy in newly diagnosed patients with cardiac stage IIIb AL amyloidosis","author":"Kastritis","year":"2026","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027962","article-title":"Isatuximab for relapsed and\/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)","volume":"146","author":"Parker","year":"2025","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2505133","article-title":"Measurable residual disease-guided therapy in newly diagnosed myeloma","volume":"393","author":"Perrot","year":"2025","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025899","article-title":"Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy","volume":"144","author":"Chakraborty","year":"2024","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3760\/cma.j.cn112137-20231005-00634","article-title":"Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia","volume":"104","author":"Dou","year":"2024","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2025.2519896","article-title":"Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series","volume":"30","author":"Suichi","year":"2025","journal-title":"Hematology"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m116.753145","article-title":"Interferon-\u03b3 Promotes antibody-mediated fratricide of acute myeloid leukemia cells","volume":"291","author":"Fatehchand","year":"2016","journal-title":"J Biol Chem"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021570","article-title":"A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-\u03b3-induced CD38 expression","volume":"143","author":"Murtadha","year":"2024","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05892-9","article-title":"The clinical efficacy of a daratumumab-based regimen in relapsed\/refractory acute leukemia: a single-center experience","volume":"103","author":"Dai","year":"2024","journal-title":"Ann Hematol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.022","article-title":"Targeted therapy with venetoclax and daratumumab as part of HSCT preparative regimen in children with chemorefractory acute myeloid leukemia","volume":"29","author":"Klimentova","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026118","article-title":"Dar-ting at CD38 in T-cell leukemias","volume":"144","author":"Senapati","year":"2024","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1734705","article-title":"Case Report: Dual impact of daratumumab in early T-cell precursor acute lymphoblastic leukemia -- consolidation therapy achieves remission and eliminates donor-specific HLA antibodies","volume":"17","author":"Wong","year":"2026","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1007\/s00277-024-05775-z","article-title":"Daratumumab and venetoclax combined with CAGE for late R\/R T-ALL\/LBL patients: Single-arm, open-label, phase I study","volume":"103","author":"Shi","year":"2024","journal-title":"Ann Hematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.12.013","article-title":"Phase 2 study of daratumumab in relapsed\/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma","volume":"19","author":"Salles","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B78","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood-2024-211388","article-title":"Daratumumab with dose-adjusted EPOCH is feasible in newly diagnosed plasmablastic lymphoma: AIDS Malignancy consortium 105","volume":"144","author":"Noy","year":"2024","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70875","article-title":"Daratumumab for CD20(-)CD38(+) relapsed\/refractory diffuse large B-cell lymphoma","volume":"29","author":"Hong","year":"2025","journal-title":"J Cell Mol Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164928","article-title":"Targeting CD38 with daratumumab plus chemotherapy for patients with advanced-stage plasmablastoid large B-cell lymphoma","volume":"11","author":"Ryu","year":"2022","journal-title":"J Clin Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017279","article-title":"Safety and efficacy of daratumumab in immune thrombocytopenia","volume":"10","author":"Tsykunova","year":"2026","journal-title":"Blood Adv"},{"key":"B82","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bjh.18773","article-title":"B cells and antibodies in refractory immune thrombocytopenia","volume":"203","author":"Roeser","year":"2023","journal-title":"Br J Haematol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","article-title":"Autoimmune haemolytic anaemias","volume":"10","author":"Michel","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012585","article-title":"Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease","volume":"8","author":"Jalink","year":"2024","journal-title":"Blood Adv"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02479-w","article-title":"The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA","volume":"60","author":"Giammarco","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103849","article-title":"Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial","volume":"94","author":"Chen","year":"2026","journal-title":"EClinicalMedicine"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Sci Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41467-026-69112-w","article-title":"Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial","volume":"17","author":"Ostendorf","year":"2026","journal-title":"Nat Commun"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103520","article-title":"Daratumumab monotherapy reverses the immune and pro-fibrotic profiles in refractory lupus nephritis patients: a pilot case study","volume":"158","author":"Roccatello","year":"2026","journal-title":"J Autoimmun"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002742","article-title":"Daratumumab for the treatment of refractory ANCA-associated vasculitis","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1087597","article-title":"Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2023.06.018","article-title":"Daratumumab for antibody-mediated rejection: Is it time to target the real culprit","volume":"23","author":"de Nattes","year":"2023","journal-title":"Am J Transplant"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.08.020","article-title":"Open-label phase 1\/2 study of daratumumab-based desensitization before kidney transplantation","volume":"9","author":"Pilon","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1681\/asn.0000000000000287","article-title":"Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant","volume":"35","author":"Vincenti","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2025.01.021","article-title":"Daratumumab monotherapy as a desensitization strategy prior to cardiac transplantation","volume":"44","author":"Crespo-Diaz","year":"2025","journal-title":"J Heart Lung Transplant"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/petr.70166","article-title":"Daratumumab in heart transplantation: A pilot study in a pediatric and young adult series","volume":"29","author":"Tuta","year":"2025","journal-title":"Pediatr Transplant"},{"key":"B102","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-025-01315-8","article-title":"Daratumumab for PRCA after HCT: Study and practical considerations from the EBMT Transplant Complications Working Party","volume":"15","author":"Gagelmann","year":"2025","journal-title":"Blood Cancer J"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1625365","article-title":"Effective treatment with daratumumab in post-HSCT refractory immune-mediated cytopenias: A case report and literature review","volume":"16","author":"Jing","year":"2025","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2021.11.019","article-title":"Daratumumab for donor-specific anti-HLA antibody desensitization in a case of HLA-mismatched allogeneic stem cell transplantation","volume":"45","author":"Ibrahim","year":"2023","journal-title":"Hematol Transfus Cell Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1681884","article-title":"Combination therapy of ofatumumab and daratumumab in patients with severe anti-NMDA receptor encephalitis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.70265","article-title":"Daratumumab treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A case report","volume":"13","author":"Zhang","year":"2026","journal-title":"Ann Clin Transl Neurol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15266","article-title":"Daratumumab for treatment-refractory antibody-mediated diseases in neurology","volume":"29","author":"Scheibe","year":"2022","journal-title":"Eur J Neurol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac574","article-title":"Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: A systematic review and meta-analysis","volume":"9","author":"Vassilopoulos","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"36","DOI":"10.46989\/001c.141401","article-title":"Consensus guidelines and recommendations for the anti-CD38-based therapy in clinical practice for relapsed\/refractory multiple myeloma: From the Pan-Pacific Multiple Myeloma Working Group","volume":"7","author":"Chen","year":"2025","journal-title":"Clin Hematol Int"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069","article-title":"Resolving the daratumumab interference with blood compatibility testing","volume":"55","author":"Chapuy","year":"2015","journal-title":"Transfusion"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17137","article-title":"Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping","volume":"62","author":"Chami","year":"2022","journal-title":"Transfusion"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.189159","article-title":"European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: What to use and when","volume":"103","author":"Caers","year":"2018","journal-title":"Haematologica"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028107","article-title":"Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma","volume":"146","author":"Diamond","year":"2025","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02712-5","article-title":"The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma","volume":"39","author":"Wang","year":"2025","journal-title":"Leukemia"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103623","article-title":"Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel","volume":"172","author":"Girmenia","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: A report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13789","article-title":"International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing","volume":"56","author":"Chapuy","year":"2016","journal-title":"Transfusion"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfab055","article-title":"Use of a daratumumab-specific immunofixation assay to assess possible immunotherapy interference at a major cancer center: Our experience and recommendations","volume":"6","author":"Kirchhoff","year":"2021","journal-title":"J Appl Lab Med"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfae142","article-title":"Distinguishing daratumumab from endogenous monoclonal proteins in serum from multiple myeloma patients using an automated mass spectrometry system","volume":"10","author":"Barnidge","year":"2025","journal-title":"J Appl Lab Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2021.02.011","article-title":"Clearing drug interferences in myeloma treatment using mass spectrometry","volume":"92","author":"Kohlhagen","year":"2021","journal-title":"Clin Biochem"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010162","article-title":"CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies","volume":"7","author":"Perez de Acha","year":"2023","journal-title":"Blood Adv"},{"key":"B123","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","article-title":"Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma","volume":"14","author":"Ziccheddu","year":"2024","journal-title":"Blood Cancer J"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13942","article-title":"Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma","volume":"110","author":"Abdallah","year":"2023","journal-title":"Eur J Haematol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932951\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:32:07Z","timestamp":1788269527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932951\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":125,"alternative-id":["10.3389\/fimmu.2026.1932951"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932951","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1932951"}}